Venus Concept (VERO) Competitors

Venus Concept logo
$0.31 0.00 (0.00%)
As of 11/6/2026

VERO vs. VVOS, AMIX, BBLG, NXL, and BTCY

Should you buy Venus Concept stock or one of its competitors? Venus Concept's main competitors and comparable companies include Vivos Therapeutics (VVOS), Autonomix Medical (AMIX), Bone Biologics (BBLG), Nexalin Technology (NXL), and Biotricity (BTCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Venus Concept compare to Vivos Therapeutics?

Venus Concept (NASDAQ:VERO) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Venus Concept has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.37, indicating that its share price is 537% more volatile than the broader market.

Vivos Therapeutics has lower revenue, but higher earnings than Venus Concept. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venus Concept$58.88M0.01-$47M-$48.84N/A
Vivos Therapeutics$20.90M0.07-$21.17M-$1.48N/A

In the previous week, Vivos Therapeutics had 7 more articles in the media than Venus Concept. MarketBeat recorded 7 mentions for Vivos Therapeutics and 0 mentions for Venus Concept. Vivos Therapeutics' average media sentiment score of 0.74 beat Venus Concept's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Venus Concept Neutral
Vivos Therapeutics Positive

Vivos Therapeutics has a consensus target price of $2.80, suggesting a potential upside of 3,584.21%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than Venus Concept.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Venus Concept
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Vivos Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 28.0% of Venus Concept shares are held by insiders. Comparatively, 1.4% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Venus Concept has a net margin of -92.76% compared to Vivos Therapeutics' net margin of -107.36%. Venus Concept's return on equity of -1,904.25% beat Vivos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Venus Concept-92.76% -1,904.25% -85.22%
Vivos Therapeutics -107.36%-2,325.64%-88.96%

Summary

Vivos Therapeutics beats Venus Concept on 9 of the 16 factors compared between the two stocks.

How does Venus Concept compare to Autonomix Medical?

Venus Concept (NASDAQ:VERO) and Autonomix Medical (NASDAQ:AMIX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Venus Concept has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, Autonomix Medical has a beta of -0.7, suggesting that its stock price is 170% less volatile than the broader market.

Autonomix Medical has lower revenue, but higher earnings than Venus Concept. Autonomix Medical is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venus Concept$58.88M0.01-$47M-$48.84N/A
Autonomix MedicalN/AN/A-$16.72M-$15.09N/A

In the previous week, Autonomix Medical had 2 more articles in the media than Venus Concept. MarketBeat recorded 2 mentions for Autonomix Medical and 0 mentions for Venus Concept. Venus Concept's average media sentiment score of 0.00 equaled Autonomix Medical'saverage media sentiment score.

Company Overall Sentiment
Venus Concept Neutral
Autonomix Medical Neutral

Autonomix Medical has a consensus price target of $42.00, indicating a potential upside of 3,753.21%. Given Autonomix Medical's stronger consensus rating and higher possible upside, analysts plainly believe Autonomix Medical is more favorable than Venus Concept.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Venus Concept
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Autonomix Medical
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

87.4% of Venus Concept shares are owned by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are owned by institutional investors. 28.0% of Venus Concept shares are owned by company insiders. Comparatively, 5.5% of Autonomix Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Autonomix Medical has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Autonomix Medical's return on equity of -191.88% beat Venus Concept's return on equity.

Company Net Margins Return on Equity Return on Assets
Venus Concept-92.76% -1,904.25% -85.22%
Autonomix Medical N/A -191.88%-157.15%

Summary

Autonomix Medical beats Venus Concept on 8 of the 14 factors compared between the two stocks.

How does Venus Concept compare to Bone Biologics?

Bone Biologics (NASDAQ:BBLG) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

In the previous week, Bone Biologics' average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company Overall Sentiment
Bone Biologics Neutral
Venus Concept Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bone Biologics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Venus Concept
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Bone Biologics has higher earnings, but lower revenue than Venus Concept. Bone Biologics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bone BiologicsN/AN/A-$3.11M-$1.17N/A
Venus Concept$58.88M0.01-$47M-$48.84N/A

Bone Biologics has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 5.0% of Bone Biologics shares are owned by company insiders. Comparatively, 28.0% of Venus Concept shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bone Biologics has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Bone Biologics' return on equity of -57.07% beat Venus Concept's return on equity.

Company Net Margins Return on Equity Return on Assets
Bone BiologicsN/A -57.07% -52.54%
Venus Concept -92.76%-1,904.25%-85.22%

Summary

Bone Biologics beats Venus Concept on 6 of the 9 factors compared between the two stocks.

How does Venus Concept compare to Nexalin Technology?

Nexalin Technology (NASDAQ:NXL) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 17.1% of Nexalin Technology shares are held by company insiders. Comparatively, 28.0% of Venus Concept shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Nexalin Technology has higher earnings, but lower revenue than Venus Concept. Nexalin Technology is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nexalin Technology$300K3.50-$8.22M-$13.94N/A
Venus Concept$58.88M0.01-$47M-$48.84N/A

In the previous week, Nexalin Technology had 2 more articles in the media than Venus Concept. MarketBeat recorded 2 mentions for Nexalin Technology and 0 mentions for Venus Concept. Venus Concept's average media sentiment score of 0.00 beat Nexalin Technology's score of -1.01 indicating that Venus Concept is being referred to more favorably in the news media.

Company Overall Sentiment
Nexalin Technology Negative
Venus Concept Neutral

Nexalin Technology has a beta of 4.31, indicating that its stock price is 331% more volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

Venus Concept has a net margin of -92.76% compared to Nexalin Technology's net margin of -3,384.12%. Nexalin Technology's return on equity of -445.53% beat Venus Concept's return on equity.

Company Net Margins Return on Equity Return on Assets
Nexalin Technology-3,384.12% -445.53% -256.45%
Venus Concept -92.76%-1,904.25%-85.22%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nexalin Technology
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Venus Concept
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Nexalin Technology beats Venus Concept on 7 of the 13 factors compared between the two stocks.

How does Venus Concept compare to Biotricity?

Venus Concept (NASDAQ:VERO) and Biotricity (NASDAQ:BTCY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Biotricity has lower revenue, but higher earnings than Venus Concept. Biotricity is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venus Concept$58.88M0.01-$47M-$48.84N/A
Biotricity$12.06M0.09-$14.09M-$0.14N/A

Biotricity has a net margin of -80.42% compared to Venus Concept's net margin of -92.76%. Biotricity's return on equity of 0.00% beat Venus Concept's return on equity.

Company Net Margins Return on Equity Return on Assets
Venus Concept-92.76% -1,904.25% -85.22%
Biotricity -80.42%N/A -188.47%

Venus Concept has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Biotricity has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Venus Concept
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Biotricity
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 28.0% of Venus Concept shares are held by insiders. Comparatively, 1.6% of Biotricity shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Venus Concept's average media sentiment score of 0.00 equaled Biotricity'saverage media sentiment score.

Company Overall Sentiment
Venus Concept Neutral
Biotricity Neutral

Summary

Venus Concept and Biotricity tied by winning 6 of the 12 factors compared between the two stocks.

Get Venus Concept News Delivered to You Automatically

Sign up to receive the latest news and ratings for VERO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VERO vs. The Competition

MetricVenus ConceptHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$442K$5.92B$7.72B$11.67B
Dividend YieldN/A1.69%2.47%4.56%
P/E Ratio-0.0135.1732.3428.14
Price / Sales0.014.998.355.64
Price / CashN/A23.3720.8521.62
Price / Book0.074.204.443.72
Net Income-$47M$143.14M$3.51B$394.03M
7 Day PerformanceN/A-3.62%-4.69%-4.67%
1 Month PerformanceN/A-4.18%-5.66%-7.21%
1 Year Performance-83.57%-0.09%-1.17%-7.05%

Venus Concept Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VERO
Venus Concept
N/A$0.31
flat
N/AN/A$442K$58.88MN/A410
VVOS
Vivos Therapeutics
2.2787 of 5 stars
$0.09
+1.6%
$2.80
+3,092.7%
-96.9%$1.77M$17.44MN/A268
AMIX
Autonomix Medical
2.2367 of 5 stars
$1.62
-12.4%
$42.00
+2,492.6%
-94.5%$1.56MN/AN/A11
BBLG
Bone Biologics
1.0252 of 5 stars
$0.35
+3.2%
N/A-82.1%$1.19MN/AN/A2
NXL
Nexalin Technology
0.5384 of 5 stars
$1.53
+4.1%
N/A-95.5%$1.12M$300KN/A8

Related Companies and Tools


This page (NASDAQ:VERO) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners